Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats by Tetsuya Tomita, Hiromi Rakugi, Hiroki Hayashi, Ryuichi Morishita, Jiao Sun, Yuka Yanagida, Shota Yoshida, Satoshi Baba, Akiko Tenma, Masayoshi Toyoura, Sotaro Kawabata, Takako Ehara, Ryoko Asaki, Makoto Sakaguchi, Hideki Tomioka, Munehisa Shimamura, Hironori Nakagami

“…This study aimed to assess the efficacy of an IL17A peptide-based vaccine on SpA manifestations in model rats.Methods HLA-B27/human β2-microglobulin (hβ2M) transgenic rats were immunised with heat-inactivated Mycobacterium tuberculosis (MT) to develop spondylitis and arthritis as an experimental SpA model after immunisation with a keyhole limpet hemocyanin-conjugated IL17A peptide-based vaccine with an alum adjuvant three times. …”
Get full text

Unravelling the association between endometriosis and immunological diseases by Shigesi, N

“…In the cross-sectional study, women with endometriosis were found to have a significantly increased risk for (systemic) lupus erythematosus, rheumatoid arthritis, coeliac disease, myasthenia gravis, inflammatory bowel disease, osteoarthritis, gout (including pseudogout, crystal arthropathy), ankylosing spondylitis and a borderline significant risk for type 1 diabetes, ulcerative colitis and psoriasis. …”

Can we characterize A-P/IAP behavioural phenotypes in people with chronic pain? by Vaidhehi Veena Sanmugananthan, Vaidhehi Veena Sanmugananthan, Joshua C. Cheng, Joshua C. Cheng, Kasey S. Hemington, Kasey S. Hemington, Anton Rogachov, Anton Rogachov, Natalie Rae Osborne, Natalie Rae Osborne, Rachael L. Bosma, Rachael L. Bosma, Junseok Andrew Kim, Junseok Andrew Kim, Robert D. Inman, Robert D. Inman, Karen Deborah Davis, Karen Deborah Davis, Karen Deborah Davis

“…Behavioural data acquired in 43 healthy controls (HCs) and 43 age-/sex-matched people with chronic pain associated with ankylosing spondylitis (AS) was retrospectively analyzed. A-P behavioural phenotypes were based on RT differences between pain and no-pain trials of a numeric interference task. …”
Get full text

Evaluating the inhibition of IL-17A and TNFα in a cartilage explant model cultured with Th17-derived cytokines by Solveig Skovlund Groen, Anne-Christine Bay-Jensen, Christian S. Thudium, Morten H. Dziegiel, Marie Skougaard, Simon Francis Thomsen, Signe Holm Nielsen

“…Elevated levels of Th17 cells and IL-17A have been detected in skin lesions, blood, and synovial fluid from patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Moreover, IL-17A inhibitors suppress disease activity in psoriasis, PsA and AS, supporting the evidence of IL-17A contributing to the disease pathogenesis. …”
Get full text

Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies by Irmak Karaca, Elaine M. Tran, SungWho Park, Albert Bromeo, Hassan Khojasteh, Anh Ngọc Tram Tran, Negin Yavari, Amir Akhavanrezayat, Cigdem Yasar, Gunay Uludag Kirimli, Ngoc Tuong Trong Than, Muhammad Hassan, Christopher Or, Hashem Ghoraba, Diana V. Do, Quan Dong Nguyen

“…Ocular disease was idiopathic in 3 patients, and was associated with rheumatoid arthritis, IgG-4 sclerosing disease, dermatomyositis, and ankylosing spondylitis in 1 patient each. All the patients had history of previous IMT use including methotrexate (5), mycophenolate mofetil (3), azathioprine (1), tacrolimus (1), adalimumab (2), infliximab (4), and rituximab (1). …”
Get full text

Anti-tumor necrosis factor α: originators <i>versus</i> biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies by C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

“…We consequently enrolled patients affected by rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, treated with SB4, and ABP501, or with corresponding originators, belonging to the main biological prescribing centers in the Lazio region (Italy), from 2017 to 2020. …”
Get full text

Super enhancers targeting ZBTB16 in osteogenesis protect against osteoporosis by Wenhui Yu, Zhongyu Xie, Jinteng Li, Jiajie Lin, Zepeng Su, Yunshu Che, Feng Ye, Zhaoqiang Zhang, Peitao Xu, Yipeng Zeng, Xiaojun Xu, Zhikun Li, Pei Feng, Rujia Mi, Yanfeng Wu, Huiyong Shen

Get full text

Serum proteome analysis identifies a potential biomarker for axial psoriatic arthritis by Chaofan Lu, Fan Yang, Shihao He, Hongxia Yu, Qian Wang, Mengtao Li, Xiaofeng Zeng, Xiaomei Leng

“…Additionally, there was a tendency towards a positive correlation between PEDF and the Bath Ankylosing Spondylitis Disease Activity Index. Conclusions This study provided a comprehensive characterization of the proteome in axPsA and pPsA and identified a candidate biomarker, PEDF, that may contribute to early diagnosis for axPsA.…”
Get full text

Characterizing the impact of Enterococcus cecorum infection during late embryogenesis on disease progression, cecal microbiome composition, and early performance in broiler chicken... by Marcela Arango, Aaron Forga, Jing Liu, Guolong Zhang, Latasha Gray, Randy Moore, Makenly Coles, Abdiel Atencio, Carolina Trujillo, Juan David Latorre, Guillermo Tellez-Isaias, Billy Hargis, Danielle Graham

“…An additional isolate associated with enterococcal spondylitis was included in Exp 2 (EC11B). Treatment groups for Exp 2 include: 1) NC, 2) EC2, 3) EC5, 4) EC7, and 5) EC11B (n = 90–120/embryos/group). …”
Get full text

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry by Bente Glintborg, Anne Gitte Loft, Asta Linauskas, Kamilla Danebod, Dorte Vendelbo Jensen, Stavros Chrysidis, Salome Kristensen, Johnny Lillelund Raun, Natalia Manilo, Frank Mehnert, Niels Steen Krogh, Ada Colic, Heidi Lausten Munk, Hafsah Nabi, Marlene Andersen, Maren Høgberget Kalisz, Niels Lomborg, Pia Høger Thygesen, Louise Brot Christensen

“…Changes in subjective and objective measures of disease activity 4 months before and after the switch were assessed in individual patients.Results Of 1605 patients (685 RA, 314 PsA and 606 AxSpA, median disease duration was 9 years, 37% in Clinical Disease Activity Index/Ankylosing Spondylitis Disease Activity Score remission), 1171 were originator-naïve. …”
Get full text

CLINICAL AND INSTRUMENTAL CHARACTERISTICS OF AXIAL LESION IN EARLY PERIPHERAL PSORIATIC ARTHRITIS (DATA OF A REMARCA STUDY) by E. E. Gubar, E. Yu. Loginova, A. V. Smirnov, S. I. Glukhova, T. V. Korotaeva, E. L. Nasonov

“…SI on radiography (rSI) was recorded if there were changes in at least one AIJ of Kellgren grade 2 or higher; radiologically significant SI (rsSI) was diagnosed when there were changes in the AIJ, which corresponded to its lesion in ankylosing spondylitis (grade II and higher bilateral SI or grade III and higher unilateral SI). …”
Get full text

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis by Juergen Braun, Ricardo Blanco, Helena Marzo-Ortega, Lianne S. Gensler, Filip Van den Bosch, Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen van de Sande, Désirée van der Heijde, Tingting Zhuang, Anna Stefanska, Aimee Readie, Hanno B. Richards, Atul Deodhar

“…Sacroiliac (SI) joint and spinal radiographs were scored using the modified New York (mNY) grading (total sacroiliitis score; range, 0–8) and modified Stoke Ankylosing Spondylitis Spine Score (mSASSS; range, 0–72), respectively. …”
Get full text

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients by E. E. Gubar, Yu. L. Korsakova, E. Yu. Loginova, A. V. Smirnov, S. I. Glukhova, T. V. Korotaeva

“…During the treatment period, there was a significant decrease in the initially high activity of spondylitis. After 24 weeks of treatment, median BASDAI decreased from 6.0 [4.2; 7.0] to 1.4 [0.6; 3.2], median ASDAS-CRP from 3.8 [2.8; 4.4] to 1.5 [1.0; 2.1] (p=0.001 for both comparisons). …”
Get full text

Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,6... by Ylenia Ingrasciotta, Andrea Spini, Luca L'Abbate, Elena Sofia Fiore, Massimo Carollo, Valentina Ientile, Valentina Isgrò, Anna Cavazzana, Valeria Biasi, Paola Rossi, Lucian Ejlli, Valeria Belleudi, Francesca Poggi, Ester Sapigni, Aurora Puccini, Domenica Ancona, Paolo Stella, Sebastiano Pollina Addario, Alessandra Allotta, Olivia Leoni, Martina Zanforlini, Marco Tuccori, Rosa Gini, Gianluca Trifirò

“…In the real-world setting, certolizumab pegol was more commonly used by adult women with psoriasis/ankylosing spondylitis (F/M ratio: 1.8–1.9) compared to RCTs (F/M ratio: 0.5–0.6). …”
Get full text

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trial... by Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, Meghan Feely, Andris Kronbergs, Nadezhda Eberhart, Danting Zhu, Elsa Inman, Elsie Grace, Thorsten Holzkaemper, Proton Rahman, Helena Marzo-Ortega, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Sergio Schwartzman

“…Abstract Background We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)] who received ≥ 1 dose of Ixekizumab (IXE) over 5 years (PsO) or up to 3 years (PsA, axSpA). …”
Get full text

Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort studyResearch in context by Renin Chang, Thomas Yen-Ting Chen, Shiow-Ing Wang, Yao-Min Hung, Hui-Yuan Chen, Cheng-Chung James Wei

“…After matching, the COVID-19 cohort exhibited significantly higher risks of rheumatoid arthritis (aHR:2.98, 95% CI:2.78–3.20), ankylosing spondylitis (aHR:3.21, 95% CI:2.50–4.13), systemic lupus erythematosus (aHR:2.99, 95% CI:2.68–3.34), dermatopolymyositis (aHR:1.96, 95% CI:1.47–2.61), systemic sclerosis (aHR:2.58, 95% CI:2.02–3.28), Sjögren's syndrome (aHR:2.62, 95% CI:2.29–3.00), mixed connective tissue disease (aHR:3.14, 95% CI:2.26–4.36), Behçet's disease (aHR:2.32, 95% CI:1.38–3.89), polymyalgia rheumatica (aHR:2.90, 95% CI:2.36–3.57), vasculitis (aHR:1.96, 95% CI:1.74–2.20), psoriasis (aHR:2.91, 95% CI:2.67–3.17), inflammatory bowel disease (aHR:1.78, 95%CI:1.72–1.84), celiac disease (aHR:2.68, 95% CI:2.51–2.85), type 1 diabetes mellitus (aHR:2.68, 95%CI:2.51–2.85) and mortality (aHR:1.20, 95% CI:1.16–1.24). …”
Get full text

Comparative Genome Analysis of Enterococcus cecorum Reveals Intercontinental Spread of a Lineage of Clinical Poultry Isolates by Jeanne Laurentie, Valentin Loux, Christelle Hennequet-Antier, Emilie Chambellon, Julien Deschamps, Angélina Trotereau, Sylviane Furlan, Claire Darrigo, Florent Kempf, Julie Lao, Marine Milhes, Céline Roques, Benoit Quinquis, Céline Vandecasteele, Roxane Boyer, Olivier Bouchez, Francis Repoila, Jean Le Guennec, Hélène Chiapello, Romain Briandet, Emmanuelle Helloin, Catherine Schouler, Isabelle Kempf, Pascale Serror

“…ABSTRACT Enterococcus cecorum is an emerging pathogen responsible for osteomyelitis, spondylitis, and femoral head necrosis causing animal suffering and mortality and requiring antimicrobial use in poultry. …”
Get full text

Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration by Louise Linde, Lykke M. Ørnbjerg, Simon H. Rasmussen, Thorvardur Jon Love, Anne Gitte Loft, Jakub Závada, Jiří Vencovský, Karin Laas, Dan Nordstrom, Tuulikki Sokka-Isler, Bjorn Gudbjornsson, Gerdur Gröndal, Florenzo Iannone, Roberta Ramonda, Pasoon Hellamand, Eirik K. Kristianslund, Tore K. Kvien, Ana M. Rodrigues, Maria J. Santos, Catalin Codreanu, Ziga Rotar, Matija Tomšič, Isabel Castrejon, Federico Díaz-Gonzáles, Daniela Di Giuseppe, Lotta Ljung, Michael J. Nissen, Adrian Ciurea, Gary J. Macfarlane, Maureen Heddle, Bente Glintborg, Mikkel Østergaard, Merete L. Hetland

“…All PROMs (Bath Ankylosing Spondylitis Disease Activity and Functional Indices, Health Assessment Questionnaire, and patient global, pain and fatigue assessments) were more complete after 2015 (68–86%) compared to prior (50–79%). …”
Get full text

Validation of the PsAID-12 Russian questionnaire in patients with psoriatic arthritis by L. D. Vorobyeva, E. Yu. Loginova, Yu. L. Korsakova, E. E. Gubar, P. O. Tremaskina, T. V. Korotaeva

“…The number of tender joint count (TJC 68), the number of swollen joint count (SJC 66), PGA (patient global assessments) were assessed using a visual analogue scale (VAS) (0–10 cm), VAS pain (0–10 cm), BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), PsAID-12 (Psoriatic Arthritis Impact of Disease-12) and EQ-5D (EuroQoL-5D). …”
Get full text

Specific features of axial involvement in psoriatic arthritis: data from real clinical practice by E. E. Gubar, E. Yu. Loginova, Yu. L. Kоrsakova, T. V. Korotayeva, S. I. Glukhova, M. V. Sedunova, I. N. Pristavsky, I. N. Bondareva, I. F. Umnova, E. L. Nasonov

“…Disease activity was assessed using the DAS28 (Disease activity score 28), DAS (Disease activity in psoriatic arthritis) and BASDAI (Bath ankylosing spondylitis disease activity index) scales. 100 mm visual analog scale (VAS) was used for assessment of pain intensity (PI) and the Patient’s Global Assessment of Disease Activity (PtGA). …”
Get full text